Edition:
United Kingdom

Genocea Biosciences Inc (GNCA.OQ)

GNCA.OQ on NASDAQ Stock Exchange Global Market

1.07USD
15 Dec 2017
Change (% chg)

$0.03 (+2.88%)
Prev Close
$1.04
Open
$1.04
Day's High
$1.08
Day's Low
$1.02
Volume
165,369
Avg. Vol
141,827
52-wk High
$7.28
52-wk Low
$1.01

Chart for

About

Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one... (more)

Overall

Beta: 2.01
Market Cap(Mil.): $50.18
Shares Outstanding(Mil.): 28.67
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Genocea Biosciences inc qtrly ‍loss per share $0.59​

* Genocea biosciences - ‍expects existing cash and cash equivalents sufficient to support operating expenses and capital expenditure into middle of 2018​

02 Nov 2017

BRIEF-Genocea announces strategic shift to immuno-oncology and the development of neoantigen cancer vaccines

* Genocea announces strategic shift to immuno-oncology and the development of neoantigen cancer vaccines

25 Sep 2017

BRIEF-Genocea Biosciences reports qtrly loss per share $‍0.54​

* Genocea Biosciences reports second quarter 2017 financial results

09 Aug 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF83.80 -0.05
Pfizer Inc. (PFE.N) $37.20 +0.74
Merck & Co., Inc. (MRK.N) $56.24 +0.23
Sanofi SA (SASY.PA) €73.55 -0.22
AstraZeneca plc (AZN.L) 4,881.00 -3.50
GlaxoSmithKline plc (GSK.L) 1,295.00 +4.50
Vical Incorporated (VICL.OQ) $1.81 +0.02

Earnings vs. Estimates